214 related articles for article (PubMed ID: 30940999)
1. A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea.
Park HJ; Kim SJ; Song R; Chen J; Kim JH; Devadiga R; Kang HC
J Korean Med Sci; 2019 Apr; 34(12):e105. PubMed ID: 30940999
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children.
Lee SM; Kim SJ; Chen J; Song R; Kim JH; Devadiga R; Kim YK
Hum Vaccin Immunother; 2019; 15(5):1145-1153. PubMed ID: 30668217
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
[TBL] [Abstract][Full Text] [Related]
7. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
9. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.
Van den Steen P; Cheuvart B; Deraedt Q; Valdes Verelst L; Shamarina D
Hum Vaccin Immunother; 2023 Dec; 19(1):2159731. PubMed ID: 36746754
[TBL] [Abstract][Full Text] [Related]
11. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.
Munoz FM; Bond NH; Maccato M; Pinell P; Hammill HA; Swamy GK; Walter EB; Jackson LA; Englund JA; Edwards MS; Healy CM; Petrie CR; Ferreira J; Goll JB; Baker CJ
JAMA; 2014 May; 311(17):1760-9. PubMed ID: 24794369
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
15. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
17. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
[TBL] [Abstract][Full Text] [Related]
18. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
[TBL] [Abstract][Full Text] [Related]
19. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.
Jackson ML; Yu O; Nelson JC; Nordin JD; Tartof SY; Klein NP; Donahue JG; Irving SA; Glanz JM; McNeil MM; Jackson LA
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):921-925. PubMed ID: 29862604
[TBL] [Abstract][Full Text] [Related]
20. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
